Seattle, WA - (NewMediaWire) - February 27, 2019 - CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Helix TCS Inc. (OTCQB: HLIX), and its recent partnership with the State of Illinois.Helix TCS Inc. (OTCQB: HLIX), through its subsidiary BioTrackTHC, recently teamed up with the State of Illinois to measure the impact of medical cannabis on opioid use in its Opioid Alternative Pilot Program. The program could become a model for other states facing the same problems, while opening the door for more revenue opportunities for Helix TCS’ unique software solutions.The opioid epidemic has become a major health risk for the United States and Canada. After years of overprescribing, opioid addiction affects a record number of individuals that are increasingly turning to dangerous synthetic opioids. These trends have led to a growing number of overdose deaths across North America. The good news is that medical cannabis has helped turn the tide in a growing number of states.Click here to receive an investor deck and corporate updatesGrowing Opioid EpidemicDrug overdoses have become the leading cause of death of Americans under 50—and two-thirds of those deaths come from opioids. As the most prescribed class of drugs in the U.S., long-term opioid use has skyrocketed over the past several years. Painkiller prescriptions tripled from 76 million to 219 million per year between 1991 and 2011, and nowadays, nearly 300 million prescriptions are issued each year.There are many ways that regulators aim to fight the opioid epidemic. For example, methadone clinics offer long-term treatment options for addicts while behavioral treatments are designed to help people kick their addiction. The problem is that these solutions don’t address the underlying problem of nearly one-third of Americans living with chronic pain—chronic pain that needs some form of treatment.The legalization of medical cannabis across a growing number of states could offer a solution. According to the American Medical Association, states with modernized cannabis laws see a significant reduction in opioid dependence and opioid-related deaths. The assumption is that many chronic pain sufferers are amenable to using cannabinoids as an alternative treatment, and cannabinoids don’t have the same adverse side-effects.Click here to receive an investor deck and corporate updatesBioTrackTHC Powers ResearchThe State of Illinois has become a pioneer in measuring these trends with its Opioid Alternative Pilot Program. By tracking patients taking alternative medications, such as medical cannabis, the state hopes to find clear pathways to fight the nationwide epidemic. The challenge is tracking the use of medical cannabis since it occurs outside of the traditional medical system where doctors issue prescriptions purchased at pharmacies.Helix TCS Inc.’s (OTCQB: HLIX) BioTrackTHC subsidiary provides the key missing ingredient—a software application that tracks medical cannabis across the supply chain. Earlier this month, the company announced that the State of Illinois selected its software to track medical cannabis sales for patients participating in the Opioid Alternative Pilot Program, in addition to its existing tracking and tracing of the state’s medical cannabis supply chain.“Helix TCS is uniquely positioned to deliver the critical tracking and compliance technology infrastructure surrounding both forms of medicine in existing and emerging medical and recreational cannabis markets through our subsidiary, BioTrackTHC, and will be able to leverage tracking data to directly correlate changes in opioid use to medical cannabis expansion,” says Helix TCS Executive Chairman and CEO, Zachary L. Venegas.The agreement in Illinois could become a template for other states looking to implement similar programs, with key states, including New York, considering this path and also utilizing the BioTrackTHC solution for government oversight of the state’s medical cannabis ...

Company Plans to Acquire Majority Interest in Cebadora ™ Brand Yerba Mate BeveragesDenver, CO - (NewMediaWire) - February 27, 2019 - The Pocket Shot Company, (OTC: PCKK), a ten-year-old specialty alcoholic beverage distribution company based in Denver, Colorado, is pleased to announce that it has entered into a Letter of Intent (LOI) to acquire a 51% interest for stock and cash consideration in Cebadora, Inc., an early stage California based company engaged in the development of yerba mate based beverages. The letter of intent also allows The Pocket Shot Company an option to further acquire up to an 81% interest in Cebadora, Inc. “We are excited to expand our existing beverage business with our development plans for yerba mate based products infused with cannabidiol (CBD) and cannabis, in accordance with what is specifically allowed in various markets,” said David Lamadrid, CEO of the Pure Harvest Cannabis Group and the Pocket Shot Company. “Cebadora presents an ideal opportunity to offer health conscious consumers alternative products that support wellness and active life styles.” “On behalf of Cebadora, we are thrilled to be working with the team at Pure Harvest. Their resources and knowledge, both in the beverage space and in cannabis infused product lines, makes them an ideal partner for us,” stated Lucas Hildebrand, CEO of Cebadora Inc. “Pure Harvest also provides Cebadora with strategic opportunities to expand our product lines and execute our vision on a much larger scale." The Cebadora™ brand is inspired by the very popular South American tea beverage called “yerba mate”, a mineral rich stimulant known for its anti-inflammatory and antioxidant properties. The naturally caffeinated beverage is widely known as the National Drink of both Argentina and Uruguay. By long standing tradition it is a “Cebador(a)” that prepares and serves a great tasting yerba mate and ceremoniously shares with a group of friends. About the Pure Harvest Cannabis GroupThe Pure Harvest Cannabis Group is a new science-based medical cannabis company with a commitment to the highest quality products, ethical growing standards, environmental awareness, and corporate integrity. Pure Harvest intends to develop into a large scale vertically integrated producer and distributor in large, established, and growing markets.Pure Harvest is focused on developing precision dosed cannabinoid health and wellness consumer products. The Company’s goals include establishing Pure Harvest Cannabis as an iconic consumer product brand offering a wide variety of cannabis/CBD products that can be sold in multiple international markets that have legalized cannabis and hemp-derived products.Pure Harvest has recently merged with The Pocket Shot Company and plans to transition into a vertically integrated multi-state operator (MSO) and multi-country producer and purveyor of the finest quality cannabis and hemp derived products for active life styles, and to support patient health and well-being.About The Pocket Shot CompanyThe Pocket Shot Company, a portable spirit company, designs, produces, and distributes hard liquor and other beverages in flexible single-serving pouches in the United States. It offers Pocket Shot, a grab and go package for alcoholic beverages. The Company offers Pocket Shot in bourbon, whiskey, rum, vodka, brandy, tequila, cherry vodka, cinnamon whiskey, peppermint schnapps, spiced rum, and cinnamon schnapps flavors. It also offers its products through online retailers. The Pocket Shot Company was founded in 2003 and is based in Evergreen, Colorado.Forward Looking StatementsCertain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking ...

San Jose, CA and New York, NY - (NewMediaWire) - February 27, 2019 - Sonasoft Corp. (OTCQB: SSFT), a leader in innovative eDiscovery and artificial intelligence (AI) solutions, and Trusted Data Solutions (TDS), the global leader in legacy data and voice management and transformation, jointly today announced a new partnership with Cornerstone Technologies, a Sonasoft company. Cornerstone Technologies is an innovative Silicon Valley-based engineering services and product resale organization that focuses on the gathering and analyzing of data for intelligent decision making. TDS’s Evolve email archive migration solutions coupled with Cornerstone Technologies’ leadership in the migration services market offers clients a trusted and efficient path for their legacy email and data. “The demand for broad-based data archiving and large volume data migrations among mid-size and large companies seems to be unending,” said Frank Velasquez, Chief Executive Officer of Sonasoft and Cornerstone. “TDS’ impressive legacy data management experience is a perfect fit with who we are and our business model. This partnership will enable us to expand our portfolio with TDS’ suite of email archive migration technology and tape restoration services to our customers. We are increasing our capability to support even larger scale projects, while still maintaining the same level of security, defensibility, and compliance. We also see this as an opportunity to show the value of our open archiving platform and e-discovery software solution.”Similar to TDS, Cornerstone Technologies plays a pivotal role in transforming IT environments, providing data migration, eDiscovery, and other related services to help clients in healthcare, financial services, retail and high-tech sectors move forward with their technologies. “Cornerstone Technologies has established a notable footprint with its engineering and consulting solutions over the past decade,” said Marcella Arthur, vice president of marketing and channel operations at TDS. “We are excited to be joining forces and creating even bigger ripples in the space.” For more information on Trusted Data Solutions go to:https://www.trusteddata.com/For more information about the services and solutions of Cornerstone Technologies and Sonasoft, go to:https://cornerstonetechnologies.com/https://www.sonasoft.com/This news story originally was released by Trusted Data Solutions (TDS) on February 26, 2019:https://www.trusteddata.com/news/cornerstone-partnership-announcement/About Trusted Data SolutionsFor more than two decades, Trusted Data Solutions (TDS), the foremost expert in legacy data management, has set the standard for compliant access, management and transformation of voice and other electronic data. Their leadership in backup tape restoration, email archive migration, and voice logging retrieval and restoration services, coupled with their recent Voice Compliance Practice advancements, makes them a one-stop-shop for organizations requiring an all-inclusive voice managed service. TDS is the preferred choice for corporations, regulated institutions, eDiscovery specialists, government agencies and law firms that require compliant data transformation. Their industry leadership is demonstrable in their commitment to advancing their services and operations to support the demands of their growing, global customers and partners.With its North America Headquarters in New York City, and two international headquarters in the United Kingdom and Singapore, TDS maintains one of the most expansive global restoration assurance facility footprints in the market. Facilities are based in New York, New Jersey, California, Canada, England, Wales, Germany, the Netherlands, Norway, Switzerland, Australia, Hong Kong, and Singapore. Millions of customer tapes are under TDS management, equating to over 500 petabytes of data, and TDS has successfully delivered over 37 thousand projects.TDS is a wholly owned subsidiary of TDS Global Holdings which is privately held.About Cornerstone TechnologiesBased in the heart of Silicon Valley, ...

Achievement signifies Unified Payments’ commitment to excellence in financial services Miami, FL - (NewMediaWire) - February 27, 2019 - Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment including point-of-sale (“POS”), today announces Unified Payments is among the first companies to achieve self-regulatory certification from the Electronic Transactions Association. The Electronic Transactions Association ("ETA") recently announced the ETA Self-Regulation Program (“ETA SRP”) which seeks to improve security and reduce risk in the payments industry by identifying and acknowledging companies that have a deep understanding of the risks associated with financial services. The ETA is a worldwide trade association serving more than 500 member companies within the fintech payments ecosystem. The ETA Self-Regulation Program affirms the payments industry’s commitment to maintaining robust risk management programs and provides a benchmark for the industry. “The ETA SRP also demonstrates to various federal regulatory bodies that the Payments industry is not only capable of self-regulation but will continue to take concrete steps to mitigate instances of abuse.”“Being among the first payments services companies to obtain ETA SRP certification is a reflection of our commitment to excellence in our industry,” said Shawn Brown, head of risk for Net Element. “We are pleased to support this program which assures our customers and stakeholders of our dedication to utilizing best practices in every facet of our company.”About Net ElementNet Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise ("SME") in the U.S. and selected emerging markets. In the U.S., the Company aims to grow transactional revenue by innovating SME productivity services using various technology solutions and Aptito, our cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element's strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte's 2017 and 2018 Technology Fast 500™. In 2017 we were recognized by South Florida Business Journal as one of 2016's fastest-growing technology companies. Further information is available at www.NetElement.com.Forward-Looking StatementsSecurities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "continue," "will," "may," "could," "should," "expect," "expected," "plans," "intend," "anticipate," "believe," "estimate," "predict," "potential," and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include but are not limited to (i) Net Element's ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element's ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element's ability to successfully expand in existing markets and enter new markets; (iv) Net Element's ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on ...

Attains Proprietary CBD FormulationsHicksville, NY - (NewMediaWire) - February 27, 2019 - Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, vapes, isolate, gel caps and concentrate, announced today that its wholly owned subsidiary Pure Health Products (PHP) finalized its asset purchase agreement (APA) with Seven Chakras, LLC. Under the terms of this APA, which was entered into January 31, 2019, Canbiola acquired the rights and title to Seven Chakras’ proprietary formulas, methods, trade secrets related to the manufacturing of Seven Chakras products containing cannabidiol (CBD). This also includes tradename, domain name, and social media sites and other assets of Seven Chakras including but not limited to raw materials, packaging, equipment, marketing materials, and mailing lists.Seven Chakras will use their proprietary technology to infuse CBD into various consumer products, tinctures (full spectrum), salves, gels, bath (hemp massage oil) and hemp capsules products. “We believe this agreement will further strengthen and enhance Canbiola’s brand, distribution and footprint by integrating this CBD product portfolio with our current products and work towards our mission to be the premier provider of the highest quality Hemp natural products on the market,” said Marco Alfonsi, Chief Executive Officer of Canbiola.In connection with the transaction, the Company has filed a Current Report on Form 8-K on February 26, 2019 with the SEC, which includes a copy of the Asset Purchase Agreement.About Canbiola, Inc.Canbiola, Inc. (OTCQB: CANB) is a developer, manufacturer, and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, vapes, isolate, gel caps and concentrate. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. For more information about Canbiola, Inc., please visit: https://canbiola.comForward-Looking StatementsForward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.Follow Canbiola on:Twitter @CanbiolaHealthInstagram @canbiola.inc or @canbiola_cbd or @canbiola_medical_cbdFollow us on Twitter and FacebookInvestors and Media: IR@canbiola.com (516) 595-9544 Hayden IR hart@haydenir.com (917) 658-7878

Seattle, WA - (NewMediaWire) - February 27, 2019 - CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing how several states have legalized recreational cannabis over the past few years, but almost all of these states have been progressive coastal states. Last November, Michigan became the first midwestern state to legalize recreational cannabis.Let’s take a look at Michigan’s evolving regulatory framework and why Grown Rogue Inc. (CSE: GRIN) (OTC: NVSIF) has focused on building a strong presence in the state.The Marijuana Business Factbook 2018 projects that Michigan could become one of the country’s largest recreational markets, generating $1.4 billion to $1.7 billion in annual sales over the coming years, citing the state’s large existing medical cannabis population. The state’s residents are already widespread marijuana usage at around 15.6 percent of the population, compared to 14.9 percent for California.Michigan’s Complex Tiered SystemMichigan’s cannabis regulations are set to become among the most complicated in the country. After briefly closing more than 60 unlicensed medical dispensaries earlier this year, legal and supply challenges forced the state to reopen them until March 31. Many of these existing businesses have experienced issues securing new permanent licenses from the state under the new regulations—a testament to how complex the process has become.Cannabis businesses must obtain three separate licenses in order to operate in the state:State License: The state will not restrict the number of recreational licenses, but the process is still up-in-the-air. The state has issued licenses for medical cannabis businesses, but regulations on the recreational market are not finalized.Municipal License: Municipalities may prohibit or limit the number of cannabis businesses in their jurisdiction. The licensing process is completely independent of the state licensing process and many municipalities have caps in place.Real Estate: Real estate used for cannabis cultivation or retail must be approved by both the state and municipal authorities, introducing another hurdle to the cannabis business licensing process in Michigan.Legal challenges have led to an effective moratorium on the state level, as well as in several municipalities. For example, the Detroit City Council recently approved a 180-day moratorium citing ongoing legal challenges and concerns about voter-approved initiatives. The council members indicated that they would use the time to develop new ordinances to regulate the licensing and zoning of marijuana facilities and caregiver centers.Grown Rogue’s AdvantageGrown Rogue recently announced a binding agreement to expand into Michigan through a strategic partnership with Blue Zebra Community LLC. Under the terms of the deal, the partnership will include two retail dispensaries, a 19,000 sq. ft. indoor cultivation processing center in Detroit, and an interest in a 28-acre parcel located in the northern portion of the lower peninsula that could be used for cultivation.“With the second highest total number of medical cannabis card holders in the United States Michigan’s legalization of cannabis for adult-use presents a very large cannabis market opportunity,” said Obie Strickler, CEO of Grown Rogue, in a recent press release announcing the deal. “Significant barriers to entry at the local level add meaningful value to the limited number of municipal licenses approved.”The company’s partnership approach helps sidestep many of these licensing issues by acquiring assets that already have municipal licenses. In addition, these assets are strategically located in areas conducive for rapid growth.Dispensaries: Grown Rogue’s Detroit dispensary is located in midtown near popular sports stadiums, art centers, and affluent housing. The Hazel Park location is within a quarter mile of the busiest freeway system in the state, as well as population centers.Cultivation: Grown Rogue’s Detroit ...

Grass Valley, CA - (NewMediaWire) - February 27, 2019 - Simlatus Corporation (OTC PINK:SIML) (“Simlatus” or the “Company”) announces that its CBD division, Proscere Bioscience, has reached a closing date on or before March 31, 2019 with a Swiss-based CBD company. Proscere Bioscience manufactures and distributes commercial cold-water CBD extraction systems. This advanced method and technology is highly effective in producing medical-grade CBD.Richard Hylen further stated, “Our CBD extraction systems range from $750,000 for a high-end commercial system capable of 3000 gallons per day, to our low-end model costing $400,000. The company in Switzerland will receive an exclusive 5 year license with sell volume discounts of up to $50M per year. Europe is already a fertile ground for hemp and it’s growing fast thanks to the increasing consumption of other hemp-based products. In 2016, 33,000 hectares of hemp were cultivated on the continent, which equals about 81,500 acres. In the same year, the United States grew 9,650 acres.”Mr. Hylen further stated, “Our European target is the large pharmaceutical companies. Epidiolex, which is CBD based, is used to treat seizures. CBD can be used to help people suffering with a wide range of ailments. From treating pain, inflammation, infections, sleep issues and mood disorders. CBD is also proven to support the immune system, protects the brain and fights cancer. Our commercial cold-water CBD extraction system is expected to yield $225M over the next 5 years, based upon expected growth and application.” Safe Harbor for Forward-Looking Statements: This news release contains forward-looking statements which are not statements of historical fact. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to changes in general economic and financial market conditions. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.Contact: Richard Hylen, CEO Tel: (530) 205-3437

Seattle, WA - (NewMediaWire) - February 27, 2019 - CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing PotBotics Inc., a leading data aggregation and technology company in the global medical cannabis market. The company launched an innovative new vaporizer in December designed specifically for medical cannabis users. Investors may want to take a closer look at vaporizer trends and the company’s innovative approach as it looks to go public over the near-term.CFN Media recently sat down with PotBotics Co-founder and CEO David Goldstein to demonstrate the company’s innovative new vaporizer product, RYAH:Please click here to see PotBotics CEO VideoGrowing Market for VaporizersThe global e-cigarette and vaporizer market is projected to grow at a 20.8 percent compound annual growth rate to $61.4 billion by 2025, according to Research and Markets, which notes that the cannabis industry is a major source of growth in the industry. While the recreational cannabis industry represents a large potential market, vaporizers could be most impactful in the medical cannabis market where patients need alternatives to smoking.Most medical users still smoke cannabis as their primary delivery method. After all, igniting buds is the simplest way to reach temperatures needed to release cannabinoids. The problem is that smoke inhalation delivers damaging carcinogens and other materials through the bronchial tree and into the lungs. Long-term exposure to these chemicals in the lungs can lead to a range of medical conditions, including COPD and lung cancer. Ignition methods can also be very inconsistent, which makes it hard to achieve predictable results.Vaporizers are an increasingly popular alternative with fewer, if any, negative side-effects. Instead of burning buds and producing smoke, vaporizers dehydrate buds in a way that releases cannabinoids without ever catching fire. No carcinogens or other harmful chemicals ever enter the lungs, but users still benefit from the greater bioavailability of smoking versus other consumption methods that are subject to metabolism by the liver.Please Click Here to see an Investor PresentationRYAH Ensures Predictable ResultsMedical cannabis enjoys widespread support among doctors. In fact, a 2013 survey found that more than three-quarters of doctors would approve the use of medical marijuana. The problem is that there are few standardized delivery methods that guarantee dosages and measure the effects of cannabinoids in individual patients. In other words, it’s much harder for a doctor to tell a patient to go to a dispensary than for them to write a prescription.PotBotics, a leading data aggregation and technology company in the global medical cannabis market, aims to change those dynamics with its new dose-measuring vaporizer. RYAH is the first vaporizer that lets users track and control a wide range of variables—including inhalation amount and temperatures—to ensure consistent and predictable results when used with its medical-grade oil or dry herb capsules.The company’s companion app lets consumers easily set their dosing parameters and track what medicine works best for them. In addition, the data can be shared with physicians and compiled into meaningful data sets to analyze efficacy. The company’s long-term goal is to advance the understanding of cannabinoids to a point where they can predict patient outcomes by measuring both individual experiences and medical literature.“Consumers have picked up the micro-dosing trends, but unknowingly, have also accepted a lack of transparency for their medical regimen,” says PotBotics CEO David Goldstein. “RYAH is here to break that mold. We are very pleased to bring state-of-the-art technology to complement our existing suite of products in order to further understand and predict patient outcomes.”Looking AheadPotBotics Inc. has developed an innovative vaporizer that cuts through the oversaturated market to help medical cannabis patients ...

COLORADO SPRINGS, Colo., Feb. 26, 2019 (NewMediaWire) -- Gold Resource Corporation (NYSE American: GORO) (the “Company” or “GRC”) today announced an eighth consecutive year of profitability, reporting net income of $9.3 million or $0.16 per share. The Company also confirmed its previously announced 2018 annual mill production of 26,838 gold ounces and 1,672,034 silver ounces for 47,622 precious metal gold equivalent ounces. The Company announced its 2019 Oaxaca Mining Unit precious metal Outlook targeting 27,000 gold ounces and 1,700,000 silver ounces plus or minus a 10 percent range. The Company’s Nevada Mining Unit’s 2019 gold Outlook is scheduled to be announced after Isabella Pearl production commences, targeted by June 2019 or before. The Company targets its first 12 months of Isabella Pearl production to be approximately 29,000 gold ounces, plus or minus a 10% range. Gold Resource Corporation is a gold and silver producer, developer and explorer with operations in Oaxaca, Mexico and Nevada, U.S.A. The Company has returned $111 million to its shareholders in monthly dividends since commercial production commenced July 1, 2010 and offers its shareholders the option to convert their cash dividends into physical gold and silver and take delivery.2018 ANNUAL HIGHLIGHTSAchieved eighth consecutive year of profitability;Achieved 2018 gold production range with 26,838 ounces;Achieved 2018 silver production range with 1.67 million ounces;$115.3 million net sales, an increase of 5%;$9.3 million net income or $0.16 per share;$84 total cash costs after by-product credits per precious metal gold equivalent ounce sold;$655 total all-in sustaining cost per precious metal gold equivalent ounce sold;Obtained necessary permits to construct and operate Isabella Pearl Project;$15.4 million cash flow deployed to build the Isabella Pearl project;$15 million recent equity raise to fund estimated Isabella Pearl project completion;Working capital of $13.5 million;Commenced Isabella Pearl construction and completed heap leach pad;Commenced Isabella Pearl mining, crushing, and ore placement on the heap leach pad;$1.1 million distributed in shareholder dividends, totaling over $111 million since 2010;Global Proven Global Proven & Probable Reserve gold ounce increase by 17.9%, silver increase by 14.2%.2018 Overview“I am very pleased to report that for 2018, Gold Resource Corporation delivered its eighth consecutive year of profitability,” stated Gold Resource Corporation CEO and President, Mr. Jason Reid. “Our Company achieved its annual Oaxaca Mining Unit production goals at a low all-in sustaining cost per ounce of $655 and posted annual net income of $9.3 million or $0.16 per share. In May of 2018, we were granted the permits to construct and operate a mine at our Nevada Mining Unit’s Isabella Pearl project. We broke ground in June and are not only on target for our stated 12-month project build, we target first gold sales by June of 2019, if not before. We deployed $15.4 million of our cash and cash flow for Isabella Pearl construction. We also recently raised $15 million through an ATM equity program with H. C. Wainwright & CO., which we believe will provide sufficient funding to complete construction. The financing through the ATM program equated to a modest 6.3% dilution for our targeted over 100% increase in global annual gold production. We are firing on all cylinders, executing on our business plans, positioned for substantial production growth, and increased future monthly dividends. Our planning and effort for increasing shareholder value has been in the works for some time and we are excited to see our plans come to fruition.”For the year ended December 31, 2018, the Company sold 41,904 precious metal gold equivalent ounces at a total cash cost of $84 per gold equivalent ounce. Realized 2018 average sales prices were $1,259 per ounce for gold and $15.65 per ounce for silver. The Company recorded revenues of $115.3 million, and net income of $9.3 million, or ...

San Francisco, CA, Feb. 26, 2019 (NewMediaWire) -- SourcingLink.net (OTC PINK: SNET), an early stage oncology company, is a pioneering company based in San Francisco, California, USA. The company announced today that it signed a Letter of Intent to collaborate with NanoSmart Pharmaceuticals, Inc., a California-based company developing novel drug formulations to treat cancer. The collaboration includes co-development and an exclusive, world-wide license for specific formulations to treat cancer utilizing NanoSmart's proprietary ‘targeted’ drug delivery system that is designed to enhance delivery of drugs to a wide variety of cancer tumors. SourcingLink.net is excited about the collaboration opportunity because new or already-approved chemotherapy drugs can be reformulated with greater efficacy and safety for treating cancer patients. The company believes that the reformulated drugs, subject to approval by the FDA and/or regional regulatory bodies, may be used as a monotherapy, or as a ‘combo-therapy’ with SNET’s autologous cellular immuno-therapy approach, or with other therapies such as immune check point inhibitors. SNET expects to enter into a full exclusive ‘world-wide’ licensing and co-development agreement with NanoSmart under the terms of the Letter of Intent signed on February 25th, 2019. The use of NanoSmart's enhanced drug delivery platform combined with pharmacogenomics and liquid biopsy for personalizing the therapy should augment cancer drug effectiveness and safety, and improve treatment monitoring, according to the company. Currently, SNET is focused on developing its ‘core’ autologous extracorporeal immuno-therapy device for a durable response. About SourcingLink.net:SourcingLink.net, Inc. ("SNET") is a pioneering oncology company dedicated to developing , manufacturing and commercialization of therapeutics. SNET licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device. SourcingLink.net prides itself for having a world-class Advisory Board that keeps the Company leadership in the forefront of developing technologies in cancer research, biotechnology and healthcare. SourcingLink.net is currently engaging in research and development of therapeutics for oncology. SourcingLink.net is committed to its core corporate mission and values of highest U.S. Pharma Code of Conduct standards of behavior for being in compliance with the laws, regulations, company directives and guidance.Forward-looking Statements: This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which contain words such as “expect”, “believe” or “plan”, by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.One Sansome Street, Suite 3500 San Francisco, CA 94104 Phone: 415-869-1038 Fax: 415-946-8801 email: info@sourcinglink.net website: www.sourcinglink.net